As America’s aging population expands, so does the increasing need to address and conquer Alzheimer’s disease. It places significant burden on millions of Americans, their caregivers and our health care system as a whole. Despite challenges and setbacks, biopharmaceutical researchers have pushed forward in the search for lifesaving treatments and cures.

However, policies that would limit access to Alzheimer’s disease treatments, like the Centers for Medicare & Medicaid Services (CMS) proposed national coverage determination, are devastating for patients.